Sign in

    Tony Ren • Macquarie Group

    Tony Ren's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership

    Tony Ren's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership • Q3 2025

    Question

    Tony Ren of Macquarie Group asked for more detail on the Entyvio gross-to-net adjustment and its impact on the product's 11% CER growth guidance. He also inquired how Otezla's inclusion in IRA price negotiations affects plans for zasocitinib.

    Answer

    Executive Milano Furuta confirmed the adjustment was for U.S. government pricing and acknowledged it could make the 11% growth target for Entyvio challenging. CEO Christophe Weber stated that Otezla's IRA inclusion reinforces their strategy to highly differentiate zasocitinib on efficacy and safety versus existing oral treatments.

    Ask Fintool Equity Research AI

    Tony Ren's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership • Q1 2025

    Question

    Tony Ren of Macquarie Group asked about the market dynamics for Takeda's immunoglobulin in CIDP following the strong launch of a competitor, and also questioned AbbVie's aggressive targeting of frontline IBD and the absence of the ENTYVIO market share graph in the presentation.

    Answer

    Executive Julie Kim stated that expectations for immunoglobulin in CIDP are unchanged as it remains the gold standard. Regarding ENTYVIO, she reiterated its market leadership in the first-line setting and explained the share graph was omitted due to a third-party cyber incident impacting claims data, with plans to restore it once the data is reliable.

    Ask Fintool Equity Research AI